dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Porcu, Luca |
dc.contributor.author | Agbor-Tarh, Dominique Akong |
dc.contributor.author | CINIERI, Saverio |
dc.contributor.author | Franzoi, Maria Alice |
dc.contributor.author | Di Cosimo, Serena |
dc.contributor.author | Saura Manich, Cristina |
dc.contributor.author | De Santis, Maria Carmen |
dc.date.accessioned | 2021-09-10T10:04:01Z |
dc.date.available | 2021-09-10T10:04:01Z |
dc.date.issued | 2020-10-27 |
dc.identifier.citation | Di Cosimo S, Porcu L, Agbor-tarh D, Cinieri S, Franzoi MA, De Santis MC, et al. Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial. Breast Cancer Res. 2020 Oct 27;22:115. |
dc.identifier.issn | 1465-542X |
dc.identifier.uri | https://hdl.handle.net/11351/6297 |
dc.description | Índex de massa corporal; Càncer de mama HER2-positiu; Tractament neoadjuvant |
dc.description.sponsorship | The NeoALTTO study was sponsored by GlaxoSmithKline from its inception until November 30, 2015, and by Novartis since then. Lapatinib is an asset of Novartis AG as of March 2, 2015. Funding sources had no involvement in the study design, data collection, analysis and interpretation, writing of the report, and decision to submit the article for publication. |
dc.language.iso | eng |
dc.publisher | BMC |
dc.relation.ispartofseries | Breast Cancer Research;22 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Mama - Càncer - Tractament |
dc.subject | Obesitat - Fisiologia patològica |
dc.subject.mesh | Breast Neoplasms |
dc.subject.mesh | Neoadjuvant Therapy |
dc.subject.mesh | Overweight |
dc.subject.mesh | /physiopathology |
dc.title | Effect of body mass index on response to neo-adjuvant therapy in HER2-positive breast cancer: an exploratory analysis of the NeoALTTO trial |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1186/s13058-020-01356-w |
dc.subject.decs | neoplasias de la mama |
dc.subject.decs | tratamiento neoadyuvante |
dc.subject.decs | sobrepeso |
dc.subject.decs | /fisiopatología |
dc.relation.publishversion | https://doi.org/10.1186/s13058-020-01356-w |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Di Cosimo S] Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, via G.A. Amadeo 42, 20133 Milano, Italy. [Porcu L] Laboratory of Methodology for Clinical Research, Department of Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy. [Agbor-tarh D] Frontier Science (Scotland) Ltd, Kincraig, UK. [Cinieri S] San Antonio Perrino Hospital, Brindisi, Italy. [Franzoi MA] Institut Jules Bordet and l’Universitè Libre de Bruxelles (U.LB), Brussels, Belgium. [De Santis MC] Radiation Oncology, Fondazione IRSCCS Istituto Nazionale dei Tumori, Milano, Italy. [Saura C] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 33109233 |
dc.identifier.wos | 000589613500004 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |